Multi-arm multi-stage trials can improve the efficiency of the drug development process when multiple new treatments are available for testing. A group-sequential approach can be used in order to design multi-arm multi-stage trials, using an extension to Dunnett’s multiple-testing procedure. The actual sample size used in such a trial is a random variable that has high variability. This can cause problems when applying for funding as the cost will also be generally highly variable. This motivates a type of design that provides the efficiency advantages of a group-sequential multi-arm multi-stage design, but has a fixed sample size. One such design is the two-stage drop-the-losers design, in which a number of experimental treatments, and a c...
In the early stages of drug development there is often uncertainty about the most promising among a ...
In the early stages of drug development there is often uncertainty about the most promising among a ...
One family of designs that can noticeably improve efficiency in later stages of drug development are...
Multi-arm multi-stage designs can improve the efficiency of the drug-development process by evaluati...
The multi-arm multi-stage (MAMS) adaptive clinical trial design has been successfully implemented in...
Multi-arm clinical trials that compare several active treatments to a common control have been propo...
In drug development, there is often uncertainty about the most promising among a set of different tr...
Multiarm trials with follow‐up on participants are commonly implemented to assess treatment effects ...
Multiarm trials with follow-up on participants are commonly implemented to assess treatment effects ...
For many disease areas, there are often treatments in different stages of the development process. W...
Screening trials are small trials used to decide whether an intervention is sufficiently promising t...
With current success rates of confirmatory studies being only around 50%, new approaches to drug dev...
There is a growing interest in the implementation of platform trials, which provide the flexibility ...
Efficient clinical trial designs are needed to speed up the evaluation of new therapies. The multi-a...
Introduction Most literature on optimal group-sequential designs focuses on minimising the expected ...
In the early stages of drug development there is often uncertainty about the most promising among a ...
In the early stages of drug development there is often uncertainty about the most promising among a ...
One family of designs that can noticeably improve efficiency in later stages of drug development are...
Multi-arm multi-stage designs can improve the efficiency of the drug-development process by evaluati...
The multi-arm multi-stage (MAMS) adaptive clinical trial design has been successfully implemented in...
Multi-arm clinical trials that compare several active treatments to a common control have been propo...
In drug development, there is often uncertainty about the most promising among a set of different tr...
Multiarm trials with follow‐up on participants are commonly implemented to assess treatment effects ...
Multiarm trials with follow-up on participants are commonly implemented to assess treatment effects ...
For many disease areas, there are often treatments in different stages of the development process. W...
Screening trials are small trials used to decide whether an intervention is sufficiently promising t...
With current success rates of confirmatory studies being only around 50%, new approaches to drug dev...
There is a growing interest in the implementation of platform trials, which provide the flexibility ...
Efficient clinical trial designs are needed to speed up the evaluation of new therapies. The multi-a...
Introduction Most literature on optimal group-sequential designs focuses on minimising the expected ...
In the early stages of drug development there is often uncertainty about the most promising among a ...
In the early stages of drug development there is often uncertainty about the most promising among a ...
One family of designs that can noticeably improve efficiency in later stages of drug development are...